On the last Friday of the year, December 26, major U.S. indexes wrapped up the second straight week in record territory. Previously beaten down biotech names came back to life. Gilead Sciences temporarily recovered after the market corrected an overreaction to the termination of Gilead Science's agreement with Express Scripts. Earlier this week, the largest pharmacy-benefits manager in the U.S. dropped Gilead Sciences' hepatitis C drugs from its list of approved medicines. But some believe Gilead Sciences runs a strong operation regardless and could launch a large buyback program very soon. The company finished a couple percentage points higher. Gold also climbed a couple percentage points, its greatest gain in two weeks, pushing the $1,200 barrier. That is an important technical and psychological number to watch as we finish up the year -- gold finished at $1,206 in 2013.

More from Video

How to Be a Tactical Investor in the Current Market

How to Be a Tactical Investor in the Current Market

Netflix Gears Up For Earnings, Canada's Ready to Legalize Cannabis

Netflix Gears Up For Earnings, Canada's Ready to Legalize Cannabis

Activist Investing Today: Why Analysts Make Good Directors

Activist Investing Today: Why Analysts Make Good Directors

Constellation Brands COO Discusses Investing in Canopy Growth

Constellation Brands COO Discusses Investing in Canopy Growth

Canopy Growth CEO: Here's What the Future of Cannabis Looks Like for Investors

Canopy Growth CEO: Here's What the Future of Cannabis Looks Like for Investors